Stem Cell Immunogenicity Testing: Methods, Standards, and Applications

Stem cell immunogenicity testing evaluates whether stem cell preparations can provoke harmful immune responses in recipients, through the assessment of HLA expression, T-cell activation, NK-cell cytotoxicity, and complement-mediated reactions. As allogeneic and "off-the-shelf" stem cell therapies advance toward the clinic, standardized immunogenicity evaluation has become an essential element of product characterization, release testing, and regulatory submission.

Technical Overview

Immunogenicity is the capacity of a biological material to induce a specific immune response in a host, encompassing both humoral mechanisms (anti-HLA antibodies, complement-fixing antibodies) and cellular mechanisms (T-cell activation, NK-cell lysis). For stem cell products, residual or induced immunogenicity determines the risk of graft rejection, infusion reactions, accelerated clearance, and loss of therapeutic efficacy, particularly for allogeneic applications. Stem cell immunogenicity testing therefore measures the immune-interacting phenotype and functional immune-stimulating capacity of cell preparations across the product lifecycle, from early cell bank characterization to final product release.

Key determinants of stem cell immunogenicity include the expression level of HLA class I and class II molecules, co-stimulatory and adhesion molecules, immunomodulatory surface ligands, the secreted cytokine profile, and process-related impurities such as animal-derived matrix components. Notably, the immunogenic phenotype is not static: interferon-gamma exposure, cellular senescence, prolonged passaging, cryopreservation, and differentiation can all upregulate HLA and antigen-presentation machinery. Testing programs are generally designed in line with ISO 10993-20 (principles and methods for immunotoxicity testing), ISO 10993-4 (blood interaction), ISO 20387 (biobanking requirements), the GB/T 16886 series of national standards, and internationally harmonized immunotoxicity guidance such as ICH S8. Many sponsors engage accredited third-party laboratories to perform these studies under GLP or GMP-compatible quality systems.

Testing Samples

Primary and Culture-Expanded Stem Cells

Mesenchymal stromal/stem cells (MSCs) derived from bone marrow, adipose tissue, umbilical cord, Wharton's jelly, and placenta are the most frequently submitted sample type. Testing typically covers early, mid, and late passages to demonstrate immunological stability throughout the intended manufacturing window, and includes post-thaw samples to confirm that cryopreservation does not alter the immune phenotype.

Pluripotent Stem Cells and Differentiated Derivatives

Human embryonic stem cells (hESCs), induced pluripotent stem cells (hiPSCs), and their differentiated progeny, including neural progenitors, cardiomyocytes, pancreatic islet-like cells, and hepatocyte-like cells, are evaluated because differentiation can markedly change HLA expression and antigenicity. Gene-edited hypoimmune lines, such as HLA class I/II knockout or CD47-overexpressing constructs, require dedicated confirmation of their engineered low-immunogenic phenotype.

Cell Banks and Final Drug Products

Master cell banks, working cell banks, end-of-production cells, drug substance, and final drug product are all appropriate test articles. Regulatory expectations generally require immunogenicity data at the banking stage and on the clinical final formulation, administered via the intended route (intravenous, intramuscular, intra-articular, or local implantation).

Stem Cell-Derived Biologics and Combination Products

Extracellular vesicles and exosomes, conditioned media, cell lysates, and stem cells seeded onto scaffolds or hydrogels for tissue-engineered medical products are also evaluated. For combination products, both the cellular component and the biomaterial carrier are assessed for complement activation and innate immune stimulation.

Testing Items

Cell Surface Immunogenic Markers

• HLA class I (HLA-A, HLA-B, HLA-C) and class II (HLA-DR, HLA-DQ, HLA-DP) expression levels
• High-resolution HLA typing and beta-2 microglobulin quantification
• Non-classical and immunomodulatory molecules: HLA-E, HLA-G, PD-L1 (CD274), CD47, CD200
• Co-stimulatory molecules: CD80, CD86, CD40
• Adhesion molecules: ICAM-1 (CD54), VCAM-1 (CD106)
• Stress ligands for NK cells: MICA, MICB, ULBP family molecules
• ABO blood group antigens and species-specific surface markers where relevant

Functional Immune Response Assays

• One-way and two-way mixed lymphocyte reaction (MLR) using allogeneic human PBMCs
• T-cell activation markers (CD69, CD25, HLA-DR) and T-cell proliferation indices
• IFN-gamma ELISPOT and T-cell-mediated cytotoxicity (CTL) assays
• NK-cell-mediated lysis of stem cell targets
• Complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC)
• Cytokine release assays measuring IL-2, IFN-gamma, TNF-alpha, IL-6, and IL-10
• Immunosuppressive function testing for MSC products (inhibition of PBMC proliferation, Treg induction)

Immunogenic Impurities and Hemocompatibility

• Residual animal-derived components, basement membrane matrix proteins, and serum proteins
• Anti-drug antibody (ADA) screening for repeat-dose product candidates
• Complement activation markers: C3a, C5a, SC5b-9
• Hemolysis, coagulation, and platelet activation for intravenously administered products
• In silico and in vitro immunogenicity risk assessment for engineered or gene-modified lines

Testing Methods

Testing is performed using a tiered strategy that combines phenotypic characterization with functional assays, and increasingly with in vivo models for advanced allogeneic products. All methods should be validated for sensitivity, precision, and suitability for the specific cell type, ideally under ISO 17025-accredited conditions in accredited third-party laboratories or qualified GMP QC facilities.

• Multi-color flow cytometry: quantitative measurement of HLA, co-stimulatory, adhesion, and checkpoint ligands on viable cell populations
• Molecular HLA typing: PCR-SSP, PCR-SSO, sequence-based typing, and next-generation sequencing for high-resolution allele identification
• Immunoassays: ELISA and multiplex bead-based assays for secreted cytokines, immunomodulatory factors (TGF-beta, HGF, PGE2, IL-10), and complement split products
• Mixed lymphocyte reaction: proliferation quantified by CFSE dilution, tritiated thymidine or EdU incorporation, with irradiated or mitomycin-C-treated stimulator cells
• Cytotoxicity assays: lactate dehydrogenase (LDH) release, calcein-AM transfer, and chromium-51 release formats for NK-cell, CTL, CDC, and ADCC pathways
• Gene expression analysis: qPCR and transcriptome profiling of antigen-presentation and immune-evasion pathways
• Hemocompatibility panels: hemolysis ratio, plasma recalcification, and complement activation in human serum, consistent with ISO 10993-4
• In vivo immunogenicity: PBMC-humanized or HLA-transgenic mouse models to evaluate rejection kinetics, anti-HLA antibody formation, and graft persistence

Applications

Stem cell immunogenicity testing supports the entire development pipeline of cell-based therapeutics. During process development, it guides the selection of low-immunogenic starting materials, culture conditions, and passage limits. For allogeneic "off-the-shelf" products, it provides the evidence base for immune-matching strategies, including HLA matching, HLA homozygosity banking, and hypoimmune gene editing. At the regulatory stage, comprehensive immunogenicity packages accompany IND and clinical trial applications to demonstrate patient safety.

• Preclinical safety assessment and risk management of allogeneic stem cell therapies
• Quality control and batch release testing for clinical-grade stem cell products
• Qualification of master and working cell banks under ISO 20387-aligned biobanking systems
• Comparability studies after process, site, or formulation changes
• Validation of hypoimmune-engineered cell lines and gene-edited constructs
• Support for tissue-engineered medical products and cell-scaffold combination products
• Published research on immune privilege, immune evasion, and transplant tolerance mechanisms

FAQ

What is the difference between immunogenicity and immunotoxicity?

Immunogenicity describes the ability of a material to provoke a specific immune response against itself, such as anti-HLA antibody formation or T-cell sensitization. Immunotoxicity is a broader concept covering any adverse effect on the immune system, including immunosuppression, hypersensitivity, and chronic inflammation. ISO 10993-20 addresses both dimensions, while dedicated immunogenicity assays focus specifically on the rejection risk of the cell product.

Why are MSCs generally considered low-immunogenic, and does this always hold true?

MSCs typically express intermediate HLA class I, negligible HLA class II, and low co-stimulatory molecules, and they actively suppress T-cell responses through TGF-beta, HGF, PGE2, and IDO activity. However, interferon-gamma priming, senescence, long-term expansion, and certain differentiation states can upregulate HLA-DR and co-stimulatory molecules, so batch-specific functional testing remains essential.

Do autologous stem cell products require immunogenicity testing?

Yes, in a reduced scope. Although autologous products avoid allogeneic HLA mismatch, manufacturing can introduce immunogenic impurities such as animal-derived matrix components or induce neo-antigen expression through genetic instability. Residual impurity testing, surface marker characterization, and cytokine release screening are still recommended.

What sample volume and condition are required for testing?

Typical requirements range from one million to twenty million viable cells depending on the assay panel, with viability preferably above 85 percent and shipment under validated cold-chain conditions with short transit times. MLR assays additionally require healthy donor PBMCs, either freshly isolated or validated cryopreserved stocks.

How is the success of hypoimmune engineering confirmed?

Engineered lines are confirmed by demonstrating absent or markedly reduced HLA class I/II expression by flow cytometry, resistance to NK-cell lysis, diminished alloreactive T-cell proliferation in MLR, and preserved survival in complement-containing human serum. Extended in vivo persistence in humanized mouse models provides supportive evidence.

How long does a complete immunogenicity evaluation take?

Phenotypic and molecular assays can be completed within one to two weeks, whereas functional MLR, cytotoxicity, and cytokine release panels typically require three to six weeks including donor sourcing. In vivo studies in humanized models may extend across several months, so early integration into development planning is strongly advised.